E4412; A Phase 1 Study with an Expansion Cohort of the Combination of Ipilimumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

Study Overview

This phase I trial studies the side effects and best dose of ipilimumab when given together with brentuximab vedotin in treating patients with relapsed or refractory Hodgkin lymphoma.

Study Description

The purpose of this study is to determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the combination of brentuximab vedotin and ipilimumab, brentuximab vedotin and nivolumab, and brentuximab vedotin, ipilimumab, and nivolumab.

Additional Information:

Participants will not be paid for their participation.

Research Study Identifier: TX3864
ClinicalTrials.gov Identifier: NCT1310523566
Principal Investigator: Michael Robertson

Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.